Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Esflurbiprofen transdermal - Taisho Pharmaceutical

Drug Profile

Esflurbiprofen transdermal - Taisho Pharmaceutical

Alternative Names: LOQOA Tape; S-Flurbiprofen; SFPP; TT-063

Latest Information Update: 03 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tokuhon Corporation
  • Developer Taisho Pharmaceutical; Tokuhon Corporation
  • Class Analgesics; Antirheumatics; Nonsteroidal anti-inflammatories; Propionic acids
  • Mechanism of Action Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Inflammation; Pain
  • No development reported Muscle pain; Periarthritis

Most Recent Events

  • 20 Nov 2018 Teijin Pharma Corporation, Taisho Toyama Pharmaceutical and Hirosaki University Graduate School of Medicine initiate a clinical trial in Pain (In adults, In the elderly) in Japan (Topical) (UMIN000029709)
  • 09 Nov 2018 Taisho Toyama Pharmaceutical and Tokyo Medical and Dental University complete a clinical trial in Osteoarthritis in Japan (UMIN000024789)
  • 15 Feb 2018 Taisho Pharmaceutical plans a phase III trial for Osteoarthritis in February 2018 , (NCT03434197)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top